Immunovaccine Receives Financial Contribution from the Government of Canada to Provide Support Towards Clinical Studies in Co...

The National Research Council of Canada Industrial Research Assistance Program
(NRC IRAP) has provided a financial contribution of up to $407,700 to
Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV) for development
of a vaccine for respiratory syncytial virus (RSV), a common lung disease in
children, the elderly and patients with a compromised immune system. The funding
will be used to advance Immunovaccine's RSV program, including the formulation
of RSV antigens in IMV's patented DepoVax(TM) vaccine adjuvanting technology.
Extensive preclinical research has demonstrated the ability of DepoVax(TM) to
generate rapid and robust immune responses required for protection against
infectious diseases. 


"There is no vaccine currently available to protect against this disease. It is
second only to influenza as a killer of vulnerable people, taking an estimated
160,000 lives around the world each year," said John Trizzino, chief executive
officer of Immunovaccine. "We are grateful to the IRAP Industrial Technology
Advisors for being proactive in working with our company to assist in
identifying and supporting research that is directed to the most technically
challenging aspects of new product development. We very much appreciate that
IRAP recognizes the value in this research and is providing essential
non-dilutive funding to help advance this important program."


The funding will help IMV prepare for the first human trial of its DepoVax(TM)
platform technology in infectious diseases. To date, Immunovaccine has completed
Phase I clinical trials with two cancer vaccines and its first animal vaccine,
for use in cattle, is expected to move into commercial production in 2014. 


About DepoVax(TM) 

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax(TM) platform possesses impressive flexibility,
allowing it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine 

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Science Officer
[phone]
[e-mail]
www.imvaccine.com


Vida Communication (media)
Tim Brons
[phone]
[e-mail]


Brisco Capital Partners (Canadian investors)
Scott Koyich
[phone]
[e-mail]